Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
SpectronRX plans actinium-225 in Indiana
by Rick Mullin
June 16, 2022
| A version of this story appeared in
Volume 100, Issue 22
SpectronRX, a service company specializing in radiopharmaceuticals, is building an actinium-225 facility for clinical- and commercial-scale oncology therapies on a 4 hectare site in Bunker Hill, Indiana. The announcement comes amid growing interest in developing radioconjugates, drugs that deliver radiation to patients internally by attaching radionuclides to molecules that selectively target cancer sites. SpectronRX plans to install multiple particle accelerators to produce Ac-225 in a project set for completion in 2024.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter